KalshiKullanılabilirliği kontrol etKYC gerekliDoğrulanmış sonuçlanma verisiİyi kalibreSeçili emir defteri orta fiyatı
Before Jan 20, 2029 · —
Seçili emir defteri yükleniyor…
—
Kayıtlı fiyat
Before Jan 20, 2029 50.5%3 seçenek arasında lider
Before Jan 20, 2029 50.5%Piyasa kalitesi
40 / 100
Düşük kalite24s Hacim
—
Açık pozisyon
₺268,6 B
Orta açık pozisyonAlış / Satış
— / —
Before Jan 20, 2029Spread
—
Piyasa verileri
49 dakika önce güncellendi
Gecikmeli24 Ağu 26 14:00 UTC1 Oca 27 04:59 UTC
Grafik ve değişimler, seçili canlı emir defterini değil kayıtlı geçmiş olasılıkları gösterir.
Trendler
Seçili satır: emir defteri orta fiyatı. Diğer satırlar: normalleştirilmiş olabilen kayıtlı referanslar; 24 saatlik değişimler kayıtlı geçmişi kullanır.
İşlem platformu koşulları
Kaynak: Kalshi
Bu koşullar yalnızca bilgi amaçlıdır; CoinRithm deneme işlemlerinde kendi kurallarını uygular.
- Erken kapanış:
- Evet
- Sonuçlandırma süresi:
- 30m (bilgi amaçlı)
Piyasa derinliği · Before Jan 20, 2029
Seçili emir defteri yükleniyor…
—
Kurallar
If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 20, 2029, then the market resolves to Yes.
- GLP-1 drugs are already covered under Part D for type 2 diabetes, cardiovascular risk reduction and obstructive sleep apnea. Those indications are outside this market, which turns on coverage for obesity or chronic weight management. Only a completed CMS action that provides the coverage counts, such as a final rule, a finalized model design, or guidance to Part D sponsors through the Health Plan Management System. Where the White House or HHS makes the determination, the CMS document adopting it resolves this market, on the date of that document. The following do NOT resolve this market to YES: A CMS communication that discusses, studies or reports on such coverage. A proposed rule or a request for applications, which propose coverage rather than provide it. An action that considers the change and declines to make it. The Medicare GLP-1 Bridge, or extending or replacing it, because it sits outside the Part D benefit. An announcement covering only the Medicaid portion of the BALANCE Model. Coverage of a single drug, or of a subset of Part D enrollees, is sufficient. The announcement date governs, not the date coverage takes effect.
Her sonucun kuralı
- Before Jan 20, 2029
- If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 20, 2029, then the market resolves to Yes.
- Before Jan 1, 2028
- If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 1, 2028, then the market resolves to Yes.
- Before Jan 1, 2027
- If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 1, 2027, then the market resolves to Yes.
